טוען...
Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2
Currently, the dichotomous definition of human epidermal growth factor receptor 2 (HER2)-positive versus HER2-negative disease undergoing a change through inclusion of the identification of the “HER2-low” category, for which new therapeutic compounds in the form of potent antibody drug conjugates (A...
שמור ב:
| הוצא לאור ב: | Breast Care (Basel) |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
S. Karger GmbH
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7768135/ https://ncbi.nlm.nih.gov/pubmed/33447231 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000510998 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|